Literature DB >> 24870588

Intravenous immunoglobulin preparation prevents the production of pro-inflammatory cytokines by modulating NFκB and MAPKs pathways in the human monocytic THP-1 cells stimulated with procalcitonin.

Kazuki Murakami1, Chiaki Suzuki, Akihiro Fujii, Fujio Kobayashi, Atsushi Nakano, Akihito Kamizono.   

Abstract

OBJECTIVE: In the previous investigations, we showed that intravenous immunoglobulin (IVIG) prevented cytokine release in procalcitonin (PCT)-stimulated monocytic cells. The aim of the present study was to investigate the underlying mechanisms of inhibition of IVIG on cytokine production in PCT-stimulated THP-1 cells.
METHODS: THP-1 cells treated with phorbol myristate acetate were stimulated with PCT. The protein levels of pro-inflammatory cytokines [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and high-mobility group box 1 (HMGB1)] in the culture supernatants were determined using enzyme-linked immunosorbent assay kits. The mRNA level of TNF-α was determined by reverse transcription-polymerase chain reaction. The phosphorylations of nuclear factor kappa B (NFκB) and the mitogen-activated protein kinases (MAPKs) were determined by Western blotting.
RESULTS: IVIG reduced mRNA expression and protein production of TNF-α in PCT-stimulated THP-1 cells. Not only IVIG but also both the Fc fragment and the F(ab')2 fragment inhibited PCT-induced TNF-α, IL-6, and HMGB1 production. Furthermore, IVIG and its fragments suppressed PCT-induced phosphorylations of NFκB, p38 MAPK, and c-Jun N-terminal kinase.
CONCLUSIONS: Our results indicate that IVIG prevents PCT-induced cytokine production mediated by not only the Fab region but also the Fc region. The activity of IVIG and its fragments might be regulated by inhibiting NFκB and MAPKs pathways in THP-1 cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24870588     DOI: 10.1007/s00011-014-0744-2

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  26 in total

Review 1.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

2.  Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation.

Authors:  A M Cantin; B Paquette; M Richter; P Larivée
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

Review 3.  The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders.

Authors:  Mark Ballow
Journal:  J Allergy Clin Immunol       Date:  2010-12-24       Impact factor: 10.793

4.  Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production.

Authors:  T Shimozato; M Iwata; H Kawada; N Tamura
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

5.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

Review 6.  Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

Authors:  U Andersson; L Björk; U Skansén-Saphir; J Andersson
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

7.  Optimized THP-1 differentiation is required for the detection of responses to weak stimuli.

Authors:  E K Park; H S Jung; H I Yang; M C Yoo; C Kim; K S Kim
Journal:  Inflamm Res       Date:  2007-01       Impact factor: 4.575

8.  Intravenous immunoglobulin prevents release of proinflammatory cytokines in human monocytic cells stimulated with procalcitonin.

Authors:  Kazuki Murakami; Chiaki Suzuki; Akihiro Fujii; Teruaki Imada
Journal:  Inflamm Res       Date:  2012-02-22       Impact factor: 4.575

Review 9.  Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future.

Authors:  Philipp Schuetz; Werner Albrich; Beat Mueller
Journal:  BMC Med       Date:  2011-09-22       Impact factor: 8.775

10.  An fc gamma receptor-mediated upregulation of the production of interleukin 10 by intravenous immunoglobulin in bone-marrow-derived mouse dendritic cells stimulated with lipopolysaccharide in vitro.

Authors:  Akihiro Fujii; Yuko Kase; Chiaki Suzuki; Akihito Kamizono; Teruaki Imada
Journal:  J Signal Transduct       Date:  2013-06-18
View more
  5 in total

1.  Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation.

Authors:  Lisa Kozicky; Laura M Sly
Journal:  J Vis Exp       Date:  2017-12-26       Impact factor: 1.355

2.  IVIG inhibits TNF-α-induced MMP9 expression and activity in monocytes by suppressing NF-κB and P38 MAPK activation.

Authors:  Cuizhen Zhou; Min Huang; Lijian Xie; Jie Shen; Tingting Xiao; Renjian Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 3.  Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment.

Authors:  Sebastiano Cicco; Gerolamo Cicco; Vito Racanelli; Angelo Vacca
Journal:  Mediators Inflamm       Date:  2020-07-16       Impact factor: 4.711

4.  Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.

Authors:  Richard J Jones; Ram K Singh; Fazal Shirazi; Jie Wan; Hua Wang; Xiaobin Wang; Min Jin Ha; Muhamed Baljevic; Isere Kuiatse; Richard E Davis; Robert Z Orlowski
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

5.  Protective effect of Xuebijing injection on D-galactosamine- and lipopolysaccharide-induced acute liver injury in rats through the regulation of p38 MAPK, MMP-9 and HO-1 expression by increasing TIPE2 expression.

Authors:  Ming-Wei Liu; Rong Liu; Hai-Yin Wu; Wei Zhang; Jing Xia; Min-Na Dong; Wen Yu; Qiang Wang; Feng-Mei Xie; Rui Wang; Yun-Qiao Huang; Chuan-Yun Qian
Journal:  Int J Mol Med       Date:  2016-09-23       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.